GSA Capital Partners LLP Acquires Shares of 13,479 2seventy bio, Inc. (NASDAQ:TSVT)

GSA Capital Partners LLP bought a new position in shares of 2seventy bio, Inc. (NASDAQ:TSVT) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 13,479 shares of the company’s stock, valued at approximately $64,000.

Several other hedge funds have also modified their holdings of the business. SG Americas Securities LLC purchased a new stake in shares of 2seventy bio during the 3rd quarter worth $80,000. Stonepine Capital Management LLC purchased a new stake in 2seventy bio during the second quarter worth about $385,000. SkyView Investment Advisors LLC grew its position in 2seventy bio by 25.0% during the second quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock worth $48,000 after buying an additional 2,500 shares during the period. Susquehanna Fundamental Investments LLC increased its holdings in 2seventy bio by 39.1% in the second quarter. Susquehanna Fundamental Investments LLC now owns 192,319 shares of the company’s stock valued at $740,000 after buying an additional 54,076 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in shares of 2seventy bio by 50.4% during the 2nd quarter. Marshall Wace LLP now owns 667,023 shares of the company’s stock valued at $2,568,000 after acquiring an additional 223,408 shares during the period. 93.90% of the stock is owned by institutional investors and hedge funds.

2seventy bio Stock Performance

TSVT stock opened at $3.75 on Tuesday. The stock’s 50 day moving average price is $4.59 and its 200 day moving average price is $4.44. The firm has a market cap of $193.46 million, a P/E ratio of -2.05 and a beta of 1.78. 2seventy bio, Inc. has a 1 year low of $1.67 and a 1 year high of $6.40.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reduced their price objective on 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Monday, July 29th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.